

Applicants: Miragaya, et al.
Serial No.: Unassigned
Filing Date: Herewith
Docket No.: 976-28 PCT/US
Page 4

AMENDMENTS TO THE CLAIMS:

This listing of claims replaces the listing of claims in the application.

Listing of Claims:

CLAIMS

What is claimed is:

FORMULATIONS THAT CONTAIN AGENTS OF THROMBOLYTIC ACTION FOR RECTAL ADMINISTRATION

1. (Currently Amended) A formulation comprising Formulations that contain agents of thrombolyticaction for their rectal administration via rectal, the formulation comprising:
 - Proteins proteins and peptides with active thrombolytic and pharmacologically action-;
 - Oil oil Base-; and
 - Active active substances as: absorption promoters, protease inhibitors and preservers.
2. (Currently Amended) A One formulation that according to claim 1 characterized for containing proteins with thrombolytic action and/or anti-inflammatory, as streptokinase, (urokinase) and/or tisular activator of plasminogen.
3. (Currently Amended) A One formulation that according to claim 1 comprising characterized for containing recombinant streptokinase in a concentration of 50 000 – 1.500.000 UI/g.
4. (Currently Amended) A One formulation that according to claim 1 comprising characterized for containing natural streptokinase in a concentration of 50 000 – 1.500.000 UI/g.
5. (Currently Amended) A One formulation that according to claim 1 comprising characterized for containing urokinase in a concentration of 50 000 - 1.000.000 UI/g

Applicants: Miragaya, et al.
Serial No.: Unassigned
Filing Date: Herewith
Docket No.: 976-28 PCT/US
Page 5

6. (Currently Amended) A One formulation that according to claim 1 comprising characterized for containing tissue plasminogen activator in a concentration of 500000-50000000 UI/g.
7. (Currently Amended) A One formulation that according to claim 1-6 characterized for containing comprising promoters of mucosal absorption like sodium diclofenac and/or sodium salicylate.
8. (Currently Amended) A One formulation that according to claim 1 -6 characterized for containing comprising protease inhibitor.
9. (Currently Amended) A One formulation that according to claim 8 wherein characterized because the protease inhibitor is EDTA.
10. (Currently Amended) A One formulation that according to claims claim 1-7, 8 y 9 characterized because wherein the oil base is Witepsol H15.
11. (Currently Amended) A One formulation that according to claims claim 1-10 characterized because wherein the median weight of the suppository is 1-3 g.
12. (Currently Amended) A One formulation that according to claims claim 1-11 characterized for been wherein the formulation is efficacious, without systemic effects for the treatment of hemorrhoidal disease.
13. (Currently Amended) A method for the treatment of hemorrhoids comprising rectally administering to a mammal characterized by the use of proteins and peptides with thrombolytic action via rectal in a suppository formulation .
14. (Currently Amended) A One method that according to claim 13 wherein characterized because the protein with thrombolyticaction is streptokinase or peptides derivates thereof from her.
15. (Currently Amended) A One method that according to claim 13 wherein characterized because the protein with thrombolytic action is (urokinase) urokinase or peptides derived thereof derive from her.

Applicants: Miragaya, et al.
Serial No.: Unassigned
Filing Date: Herewith
Docket No.: 976-28 PCT/US
Page 6

16. (Currently Amended) A ~~One~~ method ~~that~~ according to claim 13 wherein characterized because the protein with thrombolyticaction is ~~the~~ tissue plasminogen activator or peptides derived ~~derive~~ from it.
17. (Currently Amended) The use of protein and peptides with thrombolyticaction for the treatment of hemorrhoids for characterized by ~~it~~ use via rectal administration and in a suppository formulation.
18. (Currently Amended) The use according to ~~te~~claim claim 17 wherein where the protein with thrombolytic action is streptokinase or peptides derive from ~~it her~~ for the treatment of hemorrhoids for characterized by ~~it~~ use via rectal administration and in a suppository formulation.
19. (Currently Amended) The use according to claim 17 where wherein the protein with thrombolytic action is urokinase (urokinase) or peptides derived ~~derive~~ from it for the treatment of hemorrhoids for characterized by ~~her~~ use via rectal administration and in a suppository formulation.
20. (Currently Amended) The use according to claim 17 where wherein the protein with thrombolytic action is ~~the~~ tissue plasminogen activator or peptides derived ~~derive~~ from it for the treatment of hemorrhoids for characterized by ~~it~~ use via rectal administration and in a suppository formulation.